Please ensure Javascript is enabled for purposes of website accessibility

Why Canopy Growth, Mitek Systems, and Ionis Pharmaceuticals Slumped Today

By Dan Caplinger - Aug 28, 2018 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out what investors are worried about with these stocks.

Tuesday turned out to be a relatively quiet session on Wall Street, as the S&P 500 and other major benchmarks made modest gains to continue their impressive summer rally. Between favorable economic data and continued confidence in the lasting power of a bull market that's approaching its 10th anniversary, investors seem inclined to accentuate the positive and ignore worries about future setbacks. Yet a few stocks did lose ground due to bad news affecting individual companies. Canopy Growth (CGC -9.15%)Mitek Systems (MITK -4.83%), and Ionis Pharmaceuticals (IONS -5.24%) were among the performers in the market. Here's why they did so poorly.

Canopy loses some of its high

Shares of Canopy Growth fell 7% as investors tried to put recent news in the marijuana industry into a broader context. Canopy was fortunate enough to get a major investment from spirits giant Constellation Brands, which went a long way toward validating its prospects for the future. Yet many of Canopy's peers also saw their stocks climb in the wake of the deal, as shareholders hoped that they would also attract buyout offers. Today, investors seem to be cooling off on the idea of an M&A gold rush in marijuana, but just about the only thing Canopy shareholders can be sure of is that volatility is likely to continue for the foreseeable future.

Rows of marijuana plants inside of a greenhouse

Image source: Getty Images.

Mitek suffers an executive exodus

Mitek Systems stock plunged 16% after the digital identity verification specialist said that two of its top executives were leaving the company. According to a press release, CEO Jim DeBello will make a transition out of his executive role effective Jan. 1, with Bruce Hansen taking over as chairman of Mitek's board in order to facilitate the transition process. At the same time, CFO Jeff Davison also told the company that he will leave as of the end of November to pursue another opportunity near his Montana home. Investors found the simultaneous announcement disquieting, especially in light of the rocky road the stock has seen over the past year.

Ionis looks less healthy

Finally, shares of Ionis Pharmaceuticals plummeted 16%. The pharmaceutical company suffered a significant setback when the U.S. Food and Drug Administration rejected an application for approval of candidate treatment Waylivra, which was submitted to help lower triglyceride levels in patients suffering from an unusual genetic disorder. The company, along with partner Akcea Therapeutics, had scraped out a close positive vote from the FDA advisory committee that considered the drug before it went to the full body for approval, but it's uncertain exactly what motivated the final rejection decision. At this point, shareholders have to wait and see whether Ionis can find a way forward for Waylivra without major delay and cost.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$37.40 (-5.24%) $-2.07
Mitek Systems Stock Quote
Mitek Systems
MITK
$8.66 (-4.83%) $0.44
Canopy Growth Stock Quote
Canopy Growth
CGC
$4.71 (-9.15%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.